A significant plunge in Chinese holiday ticket sales is more than a bad week for Imax. It is a verdict on its business model. The company’s success in its most important market, it turns out, depends less on expanding its physical footprint than on the sheer luck of the cinematic draw. Its strategy is a high-stakes gamble on spectacle.
During the 2026 Chinese New Year holiday, Imax's ticket sales saw a steep fall from 2025. The drop was more severe than the market’s. Total box-office receipts in China also fell, meaning Imax not only shrank with the market but lost ground within it. Its share of holiday ticket sales slipped. The firm’s premium pricing is only as strong as the film on screen.
The culprit was the content. The 2025 bonanza was powered by an animated fantasy epic whose visual grandeur demanded the biggest possible screen. This year’s champion was a racing comedy-drama. Though a domestic hit, its appeal lay in its characters and car chases, not its cosmic scale. Filmgoers, it seems, saw little reason to pay a premium for a bigger view of a dashboard. The technology is secondary to the spectacle.
The Chinese box office is intensely concentrated around a few key holiday periods, turning each one into a make-or-break moment.
This holiday volatility belies a rosier annual picture. The company's sales in China grew impressively in 2025 compared to the prior year. Yet this growth makes the holiday lurches more, not less, concerning. The pattern is clear. In a previous year, the firm’s holiday take was supercharged by a sprawling science-fiction blockbuster. When a sci-fi epic lands, Imax thrives. When anything else does, it struggles to justify its price.
This is not a problem confined to China. Imax’s global business is built on event films. But the dependency is more acute there. The Chinese box office is intensely concentrated around a few key holiday periods, turning each one into a make-or-break moment. In other markets, a summer of varied blockbusters can smooth out the revenue curve. In China, a single mismatched film during the New Year can define an entire quarter’s performance.
To be sure, Imax’s position in China remains formidable. Capturing a notable share of the world’s most important holiday box office with a small fraction of the country’s screens is an impressive feat of premium positioning. The company’s year-over-year revenue growth suggests a healthy underlying business. Richard Gelfond, Imax’s chief executive, often emphasises the importance of the film slate on investor calls, framing such volatility as an expected part of the business. Yet this strength is what makes the dependency so stark. The firm has built a premium network that is truly profitable only when supplied with a rare kind of cinematic fuel.
The result is a business that looks less like a technology platform and more like a film studio, hostage to the whims of producers and the tastes of audiences. For Chinese filmmakers, the significant extra cost of formatting a movie for Imax screens is a gamble. They will only take it on projects where scale is the main selling point. This narrows Imax’s potential pipeline to a very specific, and intermittent, genre. The company has built a magnificent stage. Now it must wait for a worthy play.
The question for the rest of 2026 is whether any such play is in the wings. Without another major science-fiction epic on the horizon, Imax may find itself with the best hardware in the market but little to show on it. For a company obsessed with scale, its future in its most important market depends on the smallest of things: the script.
